Enveda Banks $311M Series E, Doubling Valuation to $2B
- Enveda Biosciences closed a $311 million Series E led by Catalio Capital Management, joined by several new and existing investors.
- The round roughly doubles Enveda's valuation to about $2 billion and lifts total funding raised past $845 million.
- Enveda uses AI to mine natural-product chemistry for drug candidates and will use proceeds to push its clinical pipeline, including atopic dermatitis and metabolic disease programs, into later-stage trials.
💡 Points
A $311M Series E in this financing climate signals investors underwriting actual clinical data on two candidates, not just an AI-platform pitch. Enveda's moat is mining natural-product chemical space that synthetic-library-focused rivals ignored; the harder test is atopic dermatitis, where biologics like Dupixent already dominate and a small molecule needs a clear differentiation story to matter.
Enveda reaps $311M round to feed its ambition to become a 'household name' ↗